Semaglutide: Side Effects & Safety

Semaglutide has been extensively studied in clinical trials involving over 16,000 participants across the STEP, SUSTAIN, PIONEER, SELECT, and OASIS trial programs. The most common side effects are gastrointestinal and are typically mild to moderate, decreasing in frequency and severity with continued use and proper dose escalation.

Approximately 7% of participants discontinued treatment due to side effects in major trials — meaning 93% tolerated the medication well enough to continue. Serious adverse events are rare but include pancreatitis and potential thyroid concerns.

For a comparison of oral vs injectable side effects, see the oral vs injectable guide. For general safety context, see Are Peptides Safe?

• Nausea (20–44%): Most common, usually improves with gradual dose escalation. Worst during titration, typically subsides within 2–4 weeks at each dose level
• Diarrhea (8–30%): Mild to moderate, usually self-limiting
• Vomiting (5–24%): More common during dose increases
• Constipation (5–24%): GLP-1 agonists slow gastric emptying, which can cause constipation
• Abdominal pain (5–20%): Usually mild, may indicate dose is too high
• Headache (10–14%): Common in early treatment, typically resolves
• Injection site reactions (1–2%): Mild redness, swelling — transient
• Fatigue and dizziness: Less common, typically transient
• Hair thinning: Reported anecdotally and in post-marketing surveillance, likely related to rapid weight loss and caloric deficit rather than a direct drug effect

Managing GI side effects: Eating smaller meals, avoiding high-fat foods, staying hydrated, and following the prescribed dose escalation schedule minimizes GI symptoms. Most GI effects improve significantly after the first 4–8 weeks at each dose level.

• Pancreatitis: Acute pancreatitis has been reported — discontinue if suspected. Monitor for severe, persistent abdominal pain radiating to the back. Risk is low but clinically significant
• Thyroid C-cell tumors: Boxed warning based on rodent data showing thyroid medullary carcinoma with GLP-1 agonists. Not confirmed in humans at clinical doses, but contraindicated with personal/family history of MTC or MEN2
• Gallbladder events: Increased incidence of cholelithiasis (gallstones) and cholecystitis, likely related to rapid weight loss. Risk increases with faster and greater weight loss
• Diabetic retinopathy: Rapid glucose improvement can temporarily worsen diabetic retinopathy in patients with pre-existing disease. Ophthalmologic monitoring recommended
• Suicidal ideation: Post-marketing reports under investigation by FDA and EMA. Causal relationship not established. Monitor mood changes, especially in patients with depression history
• Muscle mass loss: Up to 25–40% of weight lost may be lean mass (muscle). Resistance training and adequate protein intake (1.2–1.6 g/kg/day) are recommended to minimize muscle loss

Contraindications:

• Personal or family history of medullary thyroid carcinoma (MTC)
• Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
• Known hypersensitivity to semaglutide
• Pregnancy and breastfeeding (discontinue at least 2 months before planned pregnancy)
• History of pancreatitis (use with caution)

Drug interactions:

• Insulin/sulfonylureas: Increased hypoglycemia risk — dose reduction of insulin or sulfonylurea may be needed
• Oral medications: Delayed gastric emptying may affect absorption of oral medications. Take time-sensitive medications (oral contraceptives, levothyroxine) separately
• Anticoagulants (warfarin): Monitor INR more frequently when initiating semaglutide, as GI absorption changes may affect warfarin levels

See the semaglutide overview for complete information. Compare with tirzepatide side effects or explore the weight loss peptides guide.